Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01586455 · ClinicalTrials.gov registry record · Phase 1
Human Placental-Derived Stem Cell Transplantation
A Phase 1 study of Batten Disease and Mucopolysaccharidosis VI, sponsored by New York Medical College.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
- 3
- Study locations
NCT01586455 is a Phase 1 study of Batten Disease and Mucopolysaccharidosis VI that has completed, run by New York Medical College. The registered enrollment target is 43 participants, below the 2,826-participant average among 11 other Batten Disease trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT01586455, a Phase 1 study of Batten Disease and Mucopolysaccharidosis VI, has completed, sponsored by New York Medical College.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full dose (high-intensity) or lower dose (low intensity) chemo- and immunotherapy followed by a stem cell transplantation with UCB and HPDSC.
Conditions Studied
Interventions
- DRUG Human Placental Derived Stem Cell
Study Locations (3)
Colorado
- Children's Hospital Colorado - Denver
New York
- New York Medical College - Valhalla
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2013-04 |
| Est. Completion | 2022-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01586455
The ClinicalTrials.gov registry entry for NCT01586455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,826-participant average among 11 other Batten Disease trials with a reported enrollment target (98% lower). The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Batten Disease appearing as the primary indexed condition, and to 1 intervention - of which Human Placental Derived Stem Cell is the first listed.
NCT01586455 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, New York, Utah.
Frequently Asked Questions
What is clinical trial NCT01586455 about?
NCT01586455 is a clinical study titled "Human Placental-Derived Stem Cell Transplantation". The purpose of this clinical trial is to investigate the safety of human placental-derived stem cells (HPDSC) given in conjunction with umbilical cord blood (UCB) stem cells in patients with various malignant or nonmalignant disorders who require a stem cell transplant. Patients will get either full...
What is the current status of trial NCT01586455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2013-04. Estimated completion is 2022-09.
What conditions does trial NCT01586455 study?
This clinical trial studies the following conditions: Batten Disease, Mucopolysaccharidosis VI, Adrenoleukodystrophy, Mucopolysaccharidosis I, Wolman Disease.
What interventions are being tested in trial NCT01586455?
The interventions under investigation include: Human Placental Derived Stem Cell (DRUG).
Who is sponsoring clinical trial NCT01586455?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01586455 being conducted?
This trial has 3 study locations across Colorado, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Batten Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
RECRUITING · Phase 1
-
Gene Therapy for Children With CLN3 Batten Disease
ACTIVE NOT RECRUITING · Phase 1
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Clinical and Neuropsychological Investigations in Batten Disease
RECRUITING
-
NYSCF Scientific Discovery Biobank
RECRUITING
-
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.